Alle Studien

20210031 A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Treatment-Naïve Unresectable or Metastatic Melanoma Studie anzeigen

ABP 206 Biosimilar A Randomized, Double-blind Study Evaluating Pharmacokinetic Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Resected Stage III or Stage IV Melanoma Subjects in the Adjuvant Setting Studie anzeigen

BI-1607 An Open-Label, Multicenter, Phase 1b/2a Clinical Trial of BI-1607, an Fc-Engineered Monoclonal Antibody to FcgRIIB (CD32b), in Combination with Ipilimumab and Pembrolizumab in Subjects with Unresectable or Metastatic Melanoma Studie anzeigen

CA224-127 / Relativity-127 A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination Versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants With Previously Untreated Metastatic or Unresectable Melanoma Studie anzeigen

CDYP688A12101 A Phase I/II, Multi-center, Open Label Study of DYP688 in Patients With Metastatic Uveal Melanoma (MUM) and Other GNAQ/11 Mutant Melanomas Studie anzeigen

CEMIfirst Bewertung der Wirksamkeit und Sicherheit von Cemiplimab als Erstlinienbehandlung des fortgeschrittenen Basalzellkarzinoms (CEMI-first) - Eine offene, einarmige, prospektive Phase-II-Studie der DeCOG Studie anzeigen

CFT1946-1101 A Phase 1/2 Open-Label Multicenter Trial to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors Studie anzeigen

DICIT Efficacy of diclofenac added to an approved, ongoing PD-1 inhibitor therapy that achieved stable disease as best response in metastatic melanoma patients. A single arm phase II trial Studie anzeigen

DODEKA | PH- IL12L19L19-01/19 A Phase I Study to Evaluate Safety and Early Signs of Efficacy of the Human Monoclonal Antibody-cytokine Fusion Protein IL12-L19L19. Studie anzeigen

DUNCAN - PH-L19IL2TNFNMSC-04/19 A Phase II Study of Intratumoral Administration of L19IL2/L19TNF in Non-melanoma Skin Cancer Patients With Presence of Injectable Lesions Studie anzeigen